Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
Sponsor: AstraZeneca
A PHASE4 clinical study on Healthy and Influenza, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 6 data snapshots since 2013. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- MedImmune LLC
For direct contact, visit the study record on ClinicalTrials.gov .